Funding for this research was provided by:
Canadian Institutes of Health Research
Fonds de Recherche du Québec - Santé
Received: 12 July 2017
Accepted: 28 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: Ethical approval was not required since this is model-based budget impact study. Data used to compute the model were retrieved from publicly available sources listed in Tables InternalRef removed and InternalRef removed.
: Not applicable.
: Two authors (FR, DR) are investigators in a Research Project (PEGASUS, ExternalRef removed) funded by Genome Canada and the Canadian Institutes for Health Research (both non-for-profit organizations funded by the Canadian government). However, this RFA required some mandatory in-kind contributions from other partners. This Research Project thus receives in-kind contributions from private corporations which either offer commercial NIPT tests (Ariosa Diagnostics Inc, San Jose, CA) or offer reagents and equipment that can be used to perform NIPT assays (Life Technologies Inc, NY, USA; Illumina, San Diego, CA, USA; QIAGEN, Hilden, GER; Perkin Elmer, Waltham, MASS, USA). This funding is at arm’s length from the scientific components of the Research Project. Other authors (NL, JAB) have no conflict of interests.